Antibody Surrogate Light Chain Constructs for Binding Diversity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods for designing antibody-like molecules with desired binding specificities and affinities, particularly in therapeutic applications, as they struggle to replicate the binding properties of native antibodies using surrogate light chain constructs.
Innovation Solution
The development of polypeptides comprising VpreB and λ5 sequences, which can be fused or non-covalently associated with antibody heavy chain sequences, forming surrogate light chain constructs that retain binding capabilities, allowing for the creation of libraries with diverse binding specificities and affinities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If surrogate light chain constructs are used to design antibody-like molecules, then the ability to create diverse binding specificities is improved, but the binding affinity and specificity compared to native antibodies deteriorates
Solution Approach 1:
The patent segments the antibody structure by separating the light chain function into surrogate components (VpreB and λ5) that can independently associate with heavy chains. This segmentation allows combinatorial diversity in binding specificity while maintaining the structural framework needed for reliable binding through the conserved heavy chain constant regions and disulfide bonding patterns.
Solution Approach 2:
The surrogate light chain constructs employ universal association mechanisms between VpreB-λ5 pairs and heavy chains through conserved interaction interfaces and disulfide bonding. This universality ensures reliable binding across diverse combinations while the variable VpreB and λ5 sequences provide the adaptability for different binding specificities.
2Reliability
If VpreB and λ5 sequences are fused or non-covalently associated with heavy chain sequences, then the formation of functional surrogate light chain constructs is achieved, but the structural complexity compared to native antibody assembly increases
Solution Approach 1:
The surrogate light chain constructs utilize self-assembly mechanisms where VpreB and λ5 sequences automatically associate with each other and with heavy chains through intrinsic disulfide bonding patterns and non-covalent interactions. This self-service approach reduces the need for complex external assembly protocols while ensuring reliable formation of functional constructs.
3Adaptability or versatility
If surrogate light chain constructs are developed for therapeutic applications, then the ability to target specific antigens is improved, but the manufacturing complexity compared to native antibody production increases
Solution Approach 1:
The patent merges the VpreB and λ5 sequences into a unified surrogate light chain construct that can be co-expressed with heavy chains in a single production system. This merging simplifies manufacturing by reducing the number of separate components that need to be purified and assembled, while still providing the adaptability for different antigen targeting through variable sequence regions.
Data Source
AI summary
The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.